Ventas Inc (VTR)vsWest Pharmaceutical Services Inc (WST)
VTR
Ventas Inc
$82.18
+0.40%
REAL ESTATE · Cap: $39.18B
WST
West Pharmaceutical Services Inc
$245.27
+1.60%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Ventas Inc generates 89% more annual revenue ($5.82B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 4.3%. VTR appears more attractively valued with a PEG of 1.74. WST earns a higher WallStSmart Score of 55/100 (C-).
VTR
Buy55
out of 100
Grade: C
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-617.7%
Fair Value
$11.94
Current Price
$82.18
$70.24 premium
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$245.27
$176.28 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 20.3%
Revenue surging 21.4% year-over-year
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Expensive relative to growth rate
ROE of 2.2% — below average capital efficiency
4.3% margin — thin
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : VTR
The strongest argument for VTR centers on Operating Margin, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : VTR
The primary concerns for VTR are PEG Ratio, Return on Equity, Profit Margin. A P/E of 158.7x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
VTR profiles as a growth stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
VTR is growing revenue faster at 21.4% — sustainability is the question.
VTR generates stronger free cash flow (368M), providing more financial flexibility.
Bottom Line
VTR scores higher overall (55/100 vs 55/100) and 21.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ventas Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other REIT - HEALTHCARE FACILITIES Stocks
Want to dig deeper into these stocks?